Lockheed Martin Declares First Quarter 2025 Dividend
BETHESDA, Md., Jan. 28, 2025 /PRNewswire/ -- The Lockheed Martin Corporation (NYSE: LMT) board of directors has authorized a first quarter 2025 dividend of $3.30 per share. The dividend is payable on March 28, 2025, to holders of record as of the close of business on March 3, 2025.
About Lockheed Martin
Lockheed Martin is a global defense technology company driving innovation and advancing scientific discovery. Our all-domain mission solutions and 21st Century Security® vision accelerate the delivery of transformative technologies to ensure those we serve always stay ahead of ready. More information at Lockheedmartin.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Life Science Labs Signal Shifting Strategies Amid New Economic Pressures, According to Survey of 550+ Researchers
ARLINGTON, Va., June 13, 2025 /PRNewswire/ -- New survey insights reveal a measurable shift in how life science labs are responding to global financial uncertainty, rising operational costs, and upcoming U.S. tariff policies. Based on responses from more than 550 academic and industry researchers, the latest data from BioInformatics' Beyond the Bench series captures how lab priorities, purchasing decisions, and funding strategies have evolved from January to mid-April 2025—offering a rare pre- and post-policy view of market sentiment. While the first wave of the survey was fielded prior to the announcement of new tariff policies, the second wave offers a timely comparison as labs began adjusting to anticipated policy changes under the Trump administration and broader macroeconomic pressures, including inflation, tightened research budgets, and supply chain strain. Click here to download the Lab Budgets & Funding Survey Key Survey Findings Include: Funding confidence is declining, with only 57% of labs reporting confidence in securing 2025 funding—down from 66% in the first wave. Financial strain is hitting North American labs harder than those in Europe: 46% report new funding challenges (vs. 21% in Europe), and over half are considering personnel cuts, compared to just 28% in Europe. 42% of labs cite new concerns about securing funding through year-end, signaling heightened financial risk across the sector. Cost-saving strategies are accelerating, including resource sharing, supplier renegotiations, outsourcing, and delayed equipment purchases. These findings reflect shifting institutional priorities and underscore the growing need for timely, market-aligned planning as labs face increased constraints and financial pressure. "By fielding this survey before and after key policy announcements, we're able to offer a real-time snapshot of how labs are adjusting to economic volatility," said Richa Singh, VP, Market Insights at BioInformatics. "As tariff policies begin to reshape lab planning, companies need focused, evidence-backed insights to align their strategies. This data helps commercial teams track funding sentiment, adapt messaging, and make confident, evidence-based decisions—especially in a market where priorities can change within weeks." About Beyond the Bench Beyond the Bench is a free monthly intelligence series created by BioInformatics to help life science and diagnostics companies understand how customer sentiment and commercial priorities are shifting—particularly during times of uncertainty and industry disruption. Powered by the Science Advisory Board, BioInformatics' proprietary network of over 55,000 life science professionals, each report delivers survey-based insights on market trends, strategic shifts, and buyer behavior. The series was launched to provide a clear, unbiased view into the evolving challenges facing researchers and decision-makers—giving commercial teams actionable guidance to align strategy, messaging, and resource planning with what matters most to their customers. Access & Get Involved: Download the Lab Budgets & Funding Survey Sign up to receive monthly Beyond the Bench reports Join the Science Advisory Board — qualify to participate in surveys, earn rewards, and shape the future of scientific research. About BioInformatics BioInformatics, part of the Science and Medicine Group, is a leading market research and advisory firm serving the life science and diagnostic industries. The company delivers custom and syndicated research powered by a proprietary global panel of more than 55,000 professionals. View original content to download multimedia: SOURCE BioInformatics Inc.
Yahoo
35 minutes ago
- Yahoo
UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times
Johnson & Johnson (NYSE:JNJ) is one of the best stocks for a retirement stock portfolio. On June 12, UBS global equity strategist Andrew Garthwaite's team pointed to Johnson & Johnson as one of the top cyclical picks, excluding financials, whose performance tends to move with the broader economy. A smiling baby with an array of baby care products in the foreground. The stock has gained over 9% in 2025 and currently offers a dividend yield of around 3.4%. Most analysts rate it as a hold, though LSEG data suggests there's still over 9% potential upside from current levels. Last month, Goldman Sachs raised its price target on Johnson & Johnson (NYSE:JNJ) from $172 to $176 and added the stock to its conviction list. The firm made the following statement in its May report: 'JNJ is a stable, defensive grower with the industry's strongest balance sheet allowing for continued high [return on invested capital] investments in the Innovative Medicines segment to augment revenue growth.' The firm highlighted that JNJ 'has a strong pipeline,' with 'meaningful revenue opportunities' in treatments for conditions such as multiple myeloma, lung cancer, and other serious illnesses. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
If You Invested $10K In Ventas Stock 10 Years Ago, How Much Would You Have Now?
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Ventas Inc. (NYSE:VTR) is a real estate investment trust, which owns, develops, and manages a diverse portfolio of properties such as senior housing communities, outpatient medical buildings, research centers, hospitals, and healthcare facilities. The company's stock traded at approximately $72.75 per share 10 years ago. If you had invested $10,000, you could have bought roughly 137 shares. Currently, shares trade at $63.45, meaning your investment's value could have declined to $8,738 from stock price depreciation. However, Ventas also paid dividends during these 10 years. Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Inspired by Uber and Airbnb – Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets – Ventas' dividend yield is currently 3.06%. Over the last 10 years, it has paid about $25.55 in dividends per share, which means you could have made $3,512 from dividends alone. Summing up $8,738 and $3,512, we end up with the final value of your investment, which is $12,250. This is how much you could have made if you had invested $10,000 in Ventas stock 10 years ago. This means a total return of 22.50%. However, this figure is significantly less than the S&P 500 total return for the same period, which was 241%. Ventas has a consensus rating of "Outperform" and a price target of $60.35 based on the ratings of 28 analysts. The price target implies a nearly 5% potential downside from the current stock price. Trending: Invest Where It Hurts — And Help Millions Heal: On April 30, the company announced its Q1 2025 earnings, posting FFO of $0.84, compared to the consensus estimate of $0.82, and revenues of $1.36 billion, compared to the consensus of $1.32 billion, as reported by Benzinga. "Ventas delivered a strong first quarter of 2025, as we executed on our strategy to capitalize on the unprecedented multiyear growth opportunity in senior housing. We drove double-digit growth in our senior housing operating portfolio, which powered our first quarter results," said CEO Debra A. Cafaro. The company reaffirmed its full-year 2025 guidance, expecting normalized FFO per share in the range of $3.35 to $3.46. Given the expected downside potential, growth-focused investors may not find Ventas stock attractive. Furthermore, they can benefit from the company's solid dividend yield of 3.06%. Check out this article by Benzinga for three more stocks offering high dividend yields. Read Next: , which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum. Maximize saving for your retirement and cut down on taxes: . Image: Shutterstock This article If You Invested $10K In Ventas Stock 10 Years Ago, How Much Would You Have Now? originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
